William J Muller

List of Publications by Year
in descending order

124 papers	12,449 citations	36203 51 h-index	25716 108 g-index
124 all docs	124 docs citations	124 times ranked	15828 citing authors

#	Article	IF	Citations
1	Emergence of Î²1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment. Oncogene, 2022, 41, 527-537.	2.6	9
2	Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. JCI Insight, 2022, 7, .	2.3	14
3	ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nature Communications, 2022, 13, 2011.	5.8	29
4	Exploiting Mouse Models to Recapitulate Clinical Tumor Dormancy and Recurrence in Breast Cancer. Endocrinology, 2022, 163, .	1.4	6
5	Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer. Oncogene, 2022, 41, 3445-3451.	2.6	2
6	Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo. Oncogene, 2021, 40, 475-491.	2.6	91
7	Abstract PS17-31: Investigating the estrogen receptor Y537S mutation in transgenic models of luminal B breast cancer. , 2021, , .		2
8	Pharmacological or genetic inhibition of iNOS prevents cachexiaâ€mediated muscle wasting and its associated metabolism defects. EMBO Molecular Medicine, 2021, 13, e13591.	3.3	9
9	Fish oil supplementation increases expression of mammary tumor apoptosis mediators and reduces inflammation in an obesity-associated HER-2 breast cancer model. Journal of Nutritional Biochemistry, 2021, 95, 108763.	1.9	9
10	Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and Î±PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clinical Cancer Research, 2020, 26, 4670-4681.	3.2	31
11	An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis. Bone Research, 2020, 8, 28.	5.4	8
12	Her-2 Breast Cancer Outcomes Are Mitigated by Consuming n-3 Polyunsaturated, Saturated, and Monounsaturated Fatty Acids Compared to n-6 Polyunsaturated Fatty Acids. Nutrients, 2020, 12, 3901.	1.7	5
13	In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches. Advances in Cancer Research, 2020, 147, 189-228.	1.9	7
14	Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR. Cell Reports, 2020, 31, 107571.	2.9	10
15	Tetraspanin CD9 is Regulated by miR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth. Cancers, 2020, 12, 795.	1.7	11
16	Point-activated ESR1^{Y541S} has a dramatic effect on the development of sexually dimorphic organs. Genes and Development, 2020, 34, 1304-1309.	2.7	10
17	An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nature Communications, 2019, 10, 2901.	5.8	24
18	Functional Redundancy between Î²1 and Î²3 Integrin in Activating the IR/Akt/mTORC1 Signaling Axis to Promote ErbB2-Driven Breast Cancer. Cell Reports, 2019, 29, 589-602.e6.	2.9	35

#	Article	IF	Citations
19	Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. Cell Reports, 2019, 29, 249-257.e8.	2.9	29
20	Mouse Models of Overexpression Reveal Distinct Oncogenic Roles for Different Type I Protein Arginine Methyltransferases. Cancer Research, 2019, 79, 21-32.	0.4	32
21	CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight, 2019, 4, .	2.3	77
22	Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance. Molecular Cancer Research, 2018, 16, 894-908.	1.5	6
23	Marine fish oil is more potent than plant-based n-3 polyunsaturated fatty acids in the prevention of mammary tumors. Journal of Nutritional Biochemistry, 2018, 55, 41-52.	1.9	23
24	In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors. Genes Chromosomes and Cancer, 2018, 57, 182-191.	1.5	13
25	The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. Cell Reports, 2018, 23, 1476-1490.	2.9	127
26	Translational and HIF-1Î±-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. Cell Metabolism, 2018, 28, 817-832.e8.	7.2	61
27	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. Nature Communications, 2018, 9, 2547.	5.8	63
28	Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib. Oncotarget, 2018, 9, 33382-33395.	0.8	7
29	Î²-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E707-E716.	3.3	22
30	The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nature Communications, 2017, 8, 14638.	5.8	52
31	Stat3 regulates centrosome clustering in cancer cells via Stathmin/PLK1. Nature Communications, 2017, 8, 15289.	5.8	36
32	Progressive polarity loss and luminal collapse disrupt tissue organization in carcinoma. Genes and Development, 2017, 31, 1573-1587.	2.7	45
33	Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Research, 2017, 19, 74.	2.2	55
34	Tumoral Vitamin D Synthesis by CYP27B1 1-Î±-Hydroxylase Delays Mammary Tumor Progression in the PyMT-MMTV Mouse Model and Its Action Involves NF-ÎºB Modulation. Endocrinology, 2016, 157, 2204-2216.	1.4	37
35	The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis. Breast Cancer Research, 2016, 18, 131.	2.2	50
36	Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. Cancer Research, 2016, 76, 4752-4764.	0.4	71

#	Article	IF	Citations
37	Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression. Cancer Research, 2016, 76, 2662-2674.	0.4	31
38	STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. Cancer Research, 2016, 76, 1416-1428.	0.4	87
39	Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity. Breast Cancer Research, 2015, 17, 7.	2.2	14
40	Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition. Molecular and Cellular Biology, 2015, 35, 4069-4082.	1.1	33
41	Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression. Breast Cancer Research, 2014, 16, R11.	2.2	21
42	ERBB2 Deficiency Alters an E2F-1-Dependent Adaptive Stress Response and Leads to Cardiac Dysfunction. Molecular and Cellular Biology, 2014, 34, 4232-4243.	1.1	10
43	Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model. BMC Cancer, 2014, 14, 509.	1.1	12
44	Cancer Affects microRNA Expression, Release, and Function in Cardiac and Skeletal Muscle. Cancer Research, 2014, 74, 4270-4281.	0.4	44
45	Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer. Cancer Cell, 2013, 24, 213-228.	7.7	678
46	LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer & Metabolism, 2013, 1, 18.	2.4	44
47	Î²-Catenin Signaling Is a Critical Event in ErbB2-Mediated Mammary Tumor Progression. Cancer Research, 2013, 73, 4474-4487.	0.4	65
48	Bcl3 Selectively Promotes Metastasis of ERBB2-Driven Mammary Tumors. Cancer Research, 2013, 73, 745-755.	0.4	63
49	p120-catenin is essential for terminal end bud function and mammary morphogenesis. Development (Cambridge), 2012, 139, 1754-1764.	1.2	39
50	Uncoupling of PI3K from ErbB3 Impairs Mammary Gland Development but Does Not Impact on ErbB2-Induced Mammary Tumorigenesis. Cancer Research, 2012, 72, 3080-3090.	0.4	23
51	Loss of the 14-3-3Ïƒ Tumor Suppressor Is a Critical Event in ErbB2-Mediated Tumor Progression. Cancer Discovery, 2012, 2, 68-81.	7.7	26
52	PGC-1Î± Promotes the Growth of ErbB2/Neuâ€“Induced Mammary Tumors by Regulating Nutrient Supply. Cancer Research, 2012, 72, 1538-1546.	0.4	45
53	Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2808-2813.	3.3	50
54	The p110Î± and p110Î² isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes and Development, 2012, 26, 1573-1586.	2.7	116

#	Article	IF	Citations
55	Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo. Breast Cancer Research, 2012, 14, R36.	2.2	23
56	HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation. Cancer Research, 2012, 72, 2672-2682.	0.4	106
57	Î²1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. Breast Cancer Research, 2011, 13, 229.	2.2	80
58	PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. Journal of Clinical Investigation, 2011, 121, 4655-4669.	3.9	110
59	Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response. Cancer Research, 2010, 70, 7776-7787.	0.4	25
60	Distinct Biological Roles for the Akt Family in Mammary Tumor Progression. Cancer Research, 2010, 70, 4260-4264.	0.4	138
61	Transcriptional Control of the ERBB2 Amplicon by ERRÎ± and PGC-1Î² Promotes Mammary Gland Tumorigenesis. Cancer Research, 2010, 70, 10277-10287.	0.4	78
62	A novel role for 14â€“3â€“3Ïƒ in regulating epithelial cell polarity. Genes and Development, 2010, 24, 947-956.	2.7	40
63	Identification of a Stat3-Dependent Transcription Regulatory Network Involved in Metastatic Progression. Cancer Research, 2009, 69, 6823-6830.	0.4	96
64	PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis. Journal of Biological Chemistry, 2009, 284, 19018-19026.	1.6	66
65	c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential. Molecular and Cellular Biology, 2009, 29, 5858-5871.	1.1	57
66	Integrins in mammary-stem-cell biology and breast-cancer progression â€“ a role in cancer stem cells?. Journal of Cell Science, 2009, 122, 207-214.	1.2	74
67	Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression. Cancer Research, 2009, 69, 5057-5064.	0.4	154
68	Signal Transduction in Transgenic Mouse Models of Human Breast Cancerâ€”Implications for Human Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 323-335.	1.0	45
69	Integrins in breast cancer dormancy. Apmis, 2008, 116, 677-684.	0.9	23
70	ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO Journal, 2008, 27, 910-920.	3.5	131
71	Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis. Cancer Research, 2008, 68, 2122-2131.	0.4	45
72	Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development. Molecular and Cellular Biology, 2007, 27, 6361-6371.	1.1	49

#	Article	IF	Citations
73	Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20302-20307.	3.3	184
74	Distinct ErbB-2â€“Coupled Signaling Pathways Promote Mammary Tumors with Unique Pathologic and Transcriptional Profiles. Cancer Research, 2007, 67, 7579-7588.	0.4	23
75	Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nature Genetics, 2007, 39, 338-346.	9.4	284
76	Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews Cancer, 2007, 7, 389-397.	12.8	222
77	Multifaceted Roles of Integrins in Breast Cancer Metastasis. Journal of Mammary Gland Biology and Neoplasia, 2007, 12, 135-142.	1.0	79
78	Î²4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis. Cell, 2006, 126, 489-502.	13.5	418
79	p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/Î²-Catenin Signaling. Cancer Research, 2006, 66, 8529-8541.	0.4	39
80	c-Src-null mice exhibit defects in normal mammary gland development and ERÎ± signaling. Oncogene, 2005, 24, 5629-5636.	2.6	58
81	The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene, 2005, 24, 7599-7607.	2.6	68
82	Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior. Clinical and Experimental Metastasis, 2005, 22, 47-59.	1.7	182
83	Effect of Conditional Knockout of the Type II TGF-Î² Receptor Gene in Mammary Epithelia on Mammary Gland Development and Polyomavirus Middle T Antigen Induced Tumor Formation and Metastasis. Cancer Research, 2005, 65, 2296-2302.	0.4	229
84	Copy Number Aberrations in Mouse Breast Tumors Reveal Loci and Genes Important in Tumorigenic Receptor Tyrosine Kinase Signaling. Cancer Research, 2005, 65, 9695-9704.	0.4	52
85	Activation of Akt-1 (PKB-Î±) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor Invasion. Cancer Research, 2004, 64, 3171-3178.	0.4	235
86	Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Development (Cambridge), 2004, 131, 5551-5560.	1.2	15
87	Targeted disruption of Î²1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell, 2004, 6, 159-170.	7.7	385
88	Estradiol Promotes Growth and Angiogenesis in Polyoma Middle T Transgenic Mouse Mammary Tumor Explants. Breast Cancer Research and Treatment, 2003, 78, 1-6.	1.1	51
89	Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. Oncogene, 2003, 22, 9151-9155.	2.6	28
90	Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases. American Journal of Pathology, 2003, 163, 2113-2126.	1.9	912

#	Article	IF	Citations
91	Transforming growth factor Î² signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8430-8435.	3.3	409
92	The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Research, 2003, 63, 3395-402.	0.4	26
93	Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Research, 2003, 63, 4920-6.	0.4	53
94	Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene, 2002, 21, 890-898.	2.6	94
95	Activation of Akt (Protein Kinase B) in Mammary Epithelium Provides a Critical Cell Survival Signal Required for Tumor Progression. Molecular and Cellular Biology, 2001, 21, 2203-2212.	1.1	262
96	Mammary epithelial-specific expression of the integrin linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene, 2001, 20, 7064-7072.	2.6	115
97	Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. Journal of Biological Chemistry, 2001, 276, 38921-38928.	1.6	74
98	Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer. Molecular and Cellular Biology, 2001, 21, 1540-1551.	1.1	147
99	Mammary gland neoplasia: insights from transgenic mouse models. BioEssays, 2000, 22, 554-563.	1.2	40
100	Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nature Medicine, 2000, 6, 306-312.	15.2	511
101	Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene, 2000, 19, 1038-1044.	2.6	87
102	Transgenic mouse models of human breast cancer. Oncogene, 2000, 19, 6130-6137.	2.6	130
103	Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway. Molecular and Cellular Biology, 2000, 20, 672-683.	1.1	342
104	Oncogene Mediated Signal Transduction in Transgenic Mouse Models of Human Breast Cancer. , 2000, 480, 185-194.		2
105	Oncogenic Activating Mutations in the neu/erbB-2 Oncogene Are Involved in the Induction of Mammary Tumors. Annals of the New York Academy of Sciences, 1999, 889, 45-51.	1.8	23
106	A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor Î± expressed from an adenovirus vector induces an antitumor response with reduced toxicity. Cancer Gene Therapy, 1999, 6, 465-474.	2.2	18
107	Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1 and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene, 1999, 18, 1663-1676.	2.6	138
108	The Role of the Epidermal Growth Factor Receptor Family in Mammary Tumorigenesis and Metastasis. Experimental Cell Research, 1999, 253, 78-87.	1.2	168

#	Article	IF	Citations
109	Accelerated Mammary Tumor Development in Mutant Polyomavirus Middle T Transgenic Mice Expressing Elevated Levels of Either the Shc or Grb2 Adapter Protein. Molecular and Cellular Biology, 1999, 19, 8169-8179.	1.1	39
110	The induction of uterine leiomyomas and mammary tumors in transgenic mice expressing polyomavirus (PyV) large T (LT) antigen is associated with the ability of PyV LT antigen to form specific complexes with retinoblastoma and CUTL1 family members. Oncogene, 1998, 16, 1963-1972.	2.6	26
111	Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. , 1998, 77, 640-644.		226
112	Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. , 1998, 77, 937-941.		58
113	CD44v3,8-10 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. Journal of Cellular Physiology, 1998, 176, 206-215.	2.0	249
114	Mammalian Grb2 Regulates Multiple Steps in Embryonic Development and Malignant Transformation. Cell, 1998, 95, 793-803.	13.5	345
115	Requirement for Both Shc and Phosphatidylinositol 3â€² Kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis. Molecular and Cellular Biology, 1998, 18, 2344-2359.	1.1	189
116	Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. , 1998, 77, 937.		1
117	CD44v3,810 is involved in cytoskeletonâ€mediated tumor cell migration and matrix metalloproteinase (MMPâ€9) association in metastatic breast cancer cells. Journal of Cellular Physiology, 1998, 176, 206-215.	2.0	4
118	Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: An animal model for CEA-directed tumor immunotherapy. , 1997, 72, 197-202.		33
119	Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: An animal model for CEA-directed tumor immunotherapy. , 1997, 72, 197.		1
120	Detection of amphiregulin and Cripto-1 in mammary tumors from transgenic mice. , 1996, 15, 44-56.		48
121	Activated neu Induces Rapid Tumor Progression. Journal of Biological Chemistry, 1996, 271, 7673-7678.	1.6	121
122	Transgenic models of breast cancer metastasis. Cancer Treatment and Research, 1996, 83, 71-88.	0.2	15
123	Activation Of The Src Family Of Tyrosine Kinases In Mammary Tumorigenesis. Advances in Cancer Research, 1994, 64, 111-123.	1.9	35
124	Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 1988, 54, 105-115.	13.5	1,097